The present invention relates to novel strains isolated from bifidobacterium adolescentis that are capable of i) increasing the transepithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 hours of treatment to over 120% of the tertiary at the onset. (ii) induce the secretion of>； 200 pg / ml of il-10, and / or iii) induce a ratio of il-10: il-12>； 1 when coincubated with human pbmcs-derived dendritic cells. Strains can have one, two, or all three of these abilities. The present invention relates to the use of such novel strains for the prevention, alleviation of symptoms, and treatment of diseases or conditions. with impaired intestinal barrier function and pro-inflammatory mucosal activation such as ibd and ibs, liver diseases such as nafld, nash, cirrhosis, and alcohol-related liver disease, metabolic disorders such as metabolic syndrome, insulin resistance, diabetes type 2, obesity, cardiovascular atherosclerosis, autoimmune diseases such as celiac disease, type 1 diabetes, multiple sclerosis and rheumatoid arthritis, and mental conditions such as major depressive disorders, a mood disorder, a cognitive chronic fatigue syndrome, and anxiety.a presente invenção refere-se a novas cepas isoladas de bifidobacterium adolescentis que são capazes de i) aumentar a resistência elétrica transepitelial (ter) de uma monocamada de células caco-2 depois de 10 horas de tratamento para mais de 120% da ter no início do tratamento, ii) induzir a secreção de >；200 pg/ml de il-10, e/ou iii) induzir uma proporção de il-10:il-12 >；1 quando coincubada com células dendríticas derivadas de pbmcs humanas. as cepas podem ter uma, duas ou todas as três dessas habilidades. a presente invenção refere-se ao uso dessas novas cepas para a prevenção, o alívio de sintomas, e o tratamento de doenças ou condições . com uma função da barreira intestinal prejudicada e ativação pró-inflamatória da mucosa , tais como ibd e ibs, doenças hepáticas tais como nafld, nash, cirrose
